T1	Participants 209 259	patients with acute severe pulmonary embolism (PE)
T2	Participants 951 1143	133 patients were included in this trial: two patients died before treatment and two were excluded retrospectively, leaving 129 patients for final analysis (67: UK 2000 + heparin; 62: UK 4400)
